Stockholm - Free Realtime Quote SEK

Active Biotech AB (publ) (ACTI.ST)

Compare
0.2860 -0.0085 (-2.89%)
As of 1:06 PM GMT+2. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
NameTitlePayExercisedYear Born
Ms. Helen Tuvesson Ph.D. President & CEO 4.04M -- 1962
Mr. Hans Kolam Chief Financial Officer -- -- 1951
Dr. Erik Vahtola Chief Medical Officer -- -- 1976

Active Biotech AB (publ)

ScheelevAegen 22
Lund, 223 63
Sweden
46 46 19 20 00 https://www.activebiotech.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
8

Description

Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that has completed phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company was incorporated in 1983 and is headquartered in Lund, Sweden.

Corporate Governance

Active Biotech AB (publ)’s ISS Governance QualityScore as of October 1, 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 1; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 7, 2024 at 10:59 AM UTC

Active Biotech AB (publ) Earnings Date

Recent Events

Related Tickers